News
31-01-2012 | reMYND receives a positive tax ruling on the income from its Roche collaboration
In the press | reMYND NV has received a positive ruling from the Belgian Tax Authorities. The ruling stipulates that the upfront license fee, all milestone payments and royalties linked to Roche Basel will qualify for the patent income deduction under Articles 205 WIB 92.
29-09-2011 | The strategic alliance between Roche and reMYND is nominated for a Scrip Award
In the press | The strategic Alliance between Roche and reMYND to develop novel therapeutics that could slow down neurodegeneration in Parkinson’s and Alzheimer’s patients is nominated for the Scrip Award “Best Partnership Alliance”. The winners will be announced in London on November 3rd, 2011. The Scrip Awards celebrate each year Excellence in the Pharmaceutical Industry.
17-08-2011 | reMYND’s grant from the Michael J Fox Foundation in SciBX
In the press | The Science-Business eXchange (SciBX, a publication by the makers of BioCentury and Nature) devoted in its recent publication an article to the role the Michael J Fox Foundation for Parkinson’s Research has been playing in the development of PD therapeutics. reMYND’s lead Parkinson program features in this article as a prime example of such support.
27-06-2011 | IWT helps to accelerate reMYND’s Diabetes program with a grant of 1.48 million EUR for 2011-2012
Press release | reMYND NV today announced that it has received a grant of 1.48 million EUR from IWT, the Flemish agency for Innovation by Science and Technology, to accelerate its Diabetes program.
09-05-2011 | reMYND’s CRO receives governmental grant for a continued innovation of its offering
On its Board Meeting of April 28th 2011, the governmental Agency for Innovation by Science and Technology (IWT) has approved a grant to reMYND’s Contract Research Organization (CRO) for the ‘Evaluation of candidate behavioral and synaptic markers in transgenic Alzheimer mouse models, to assess the feasibility of developing such early onset markers for large scale in vivo testing’, herewith recognizing the deliberated innovation efforts of the CRO.
08-02-2011 | reMYND's CRO announces quarterly digital Newsletter
With our quarterly Newsletter, we intend to provide our clients and contacts with some additional thoughts for the preclinical in-vivo testing of their experimental Alzheimer therapies. The one-pager will highlight particular aspects of our Services Offering, provide updates on new models and read-outs, and indicate opportunities for discussing in person at partnering events or scientific conferences.
15-11-2010 | Review in Nature highlights reMYND's discovery platform
In the November 2010 issue of the high impact journal Nature Reviews Drug Discovery, the News&Analysis column has been entirely devoted to the growing interest in targeting protein misfolding to therapeutically treat both rare and common diseases. The column highlights amongst others reMYND’s technology platform and the recently announced Roche-reMYND collaboration for the development of first-in-class disease-modifying treatments for Parkinson's and Alzheimer's disease.
08-09-2010 | reMYND's CRO announces publication in the International Journal of Alzheimer's Disease
The prestigious Journal of Alzheimer's Disease publishes new data on reMYND's proprietary mouse models of Alzheimer's disease: pathological hallmarks, clinical parallels, and value for drug testing in Alzheimer’s disease of the APP[V717I] London transgenic mouse model.
07-09-2010 | Roche and reMYND's DDD enter into a strategic alliance to develop first-in-class disease-modifying treatments for Parkinson's and Alzheimer's disease
Press Release | Roche (SIX: RO, ROG; OTCQX: RHHBY) and reMYND today announced that they have entered into an agreement to develop novel therapeutics that could slow down neurodegeneration in Parkinson’s and Alzheimer’s patients by inhibiting α-synuclein and tau toxicity.
